688302 海创药业
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-8.647-15.590-19.926-25.400-34.501
总资产报酬率 ROA (%)-7.277-13.984-18.233-22.191-28.216
投入资产回报率 ROIC (%)-8.107-15.252-19.603-24.075-30.526

边际利润分析
销售毛利率 (%)99.5688.428--53.571--
营业利润率 (%)-422.013-54,378.903---18,261.390--
息税前利润/营业总收入 (%)-446.885-57,305.242---18,717.369--
净利润/营业总收入 (%)-424.580-54,382.772---18,264.523--

收益指标分析
经营活动净收益/利润总额(%)120.039108.868110.388112.894113.203
价值变动净收益/利润总额(%)-8.455-6.571-8.443-9.582-7.206
营业外收支净额/利润总额(%)0.6020.0010.0020.0170.001

偿债能力分析
流动比率 (X)6.9016.02610.73711.6534.993
速动比率 (X)6.8966.02610.73711.6534.993
资产负债率 (%)19.24012.4378.3458.62719.707
带息债务/全部投入资本 (%)7.2691.734-0.3471.50210.477
股东权益/带息债务 (%)1,251.8265,561.381-28,589.6436,511.928851.995
股东权益/负债合计 (%)419.762704.0761,098.2881,059.170407.439
利息保障倍数 (X)20.02319.58625.53041.333-228.941

营运能力分析
应收账款周转天数 (天)75.1310.000--0.000--
存货周转天数 (天)982.9265.430--2.676--